Glyprothiazol

This classification denotes an anti-diabetic agent with the molecular formula C11H14N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1804FJN4MO, chemically known as 4-amino-n-(5-(1-methylethyl)-1,3,4-thiadiazol-2-yl)benzenesulfonamide but more generally known as glyprothiazol, which bears US NIH Compound Identifier 66458. European Medicines Agency schedules Glyprothiazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07957MIG. The term GLYPROTHIAZOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16, No. 3 1962, List 4). GLYPROTHIAZOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule glyprothiazol under HS 29350090 and SITC 51580. As of Q4 2014, GLYPROTHIAZOL remains US FDA's Preferred Term for this commodity. Glyprothiazol bears US NLM identifiers UMLS ID C1880994 and NCI Concept Code C65812. SMILES: CC(C)C1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N.